drugset / Trial / NCT03137537

Ivabradine in the Management of Cardiac Autonomic Dysfunction Associated With Thoracic Radiation Therapy.

NCT03137537

Phase 2 Terminated 23 enrolled Dana-Farber Cancer Institute Amgen · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will explore whether ivabradine lowers heart rate, and thus improves exercise capacity, in survivors of lymphoma who have an elevated resting heart rate as a side effect of prior radiation treatment. The drugs involved in this study are: * Ivabradine * Placebo

Timeline

Start
2018-02-27
Primary completion
2020-11-18
Completion
2020-11-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Ivabradine Small molecule Oral